Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + camrelizumab
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Disitamab vedotin + camrelizumab is a combination therapy consisting of a HER2-targeted antibody-drug conjugate (ADC) and a programmed cell death protein 1 (PD-1) inhibitor. Disitamab vedotin (RC48) is a humanized anti-HER2 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. Camrelizumab is a humanized IgG4 monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell mediated anti-tumor immune responses. This combination is primarily investigated for the treatment of HER2-expressing advanced or metastatic urothelial carcinoma, including squamous cell carcinoma and adenocarcinoma subtypes. The rationale for the combination lies in the potential synergistic effect where the ADC-induced immunogenic cell death enhances the efficacy of the checkpoint inhibitor by promoting a more inflamed tumor microenvironment.
- Brand names
- Aidexi
- Other names
- RC48-ADC + camrelizumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on disitamab vedotin + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + camrelizumab.